# US 2008/0279786 A1 · Method for Extending Lifespan Delaying the Onset of Age-Related Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0279786 A1
- Document ID: US20080279786A1
- Status: Published application
- Kind: A1
- Application number: 11/792,703
- Filed: 2005-12-15
- Published: 2008-11-13
- Earliest claimed: 2005-12-15
- Inventors: Alan B. Cash
- Web page: https://patentgrep.com/patent/US20080279786A1

## CPC

- A61K 31/22: of acyclic acids, e.g. pravastatin
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 17/18: Antioxidants, e.g. antiradicals (preparations for protection against sunlight A61Q17/00)
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 27/12: for cataracts
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method and composition for extending the lifespan of an individual and delaying the onset of age-related disease is provided. The method includes the administration of an effective dose of oxaloacetate, wherein the oxaloacetate acts to mimic the cellular conditions obtained under caloric restriction to provide similar benefits. The invention further includes methods and compositions for reducing the incidence or treatment of cancer. Compositions and methods for reducing body fat by administering an effective amount of oxaloacetate are likewise provided. Compositions for DNA repair in UV damaged cells is provided are also provided. Similarly, a method for treating a hang-over comprising administering an effective amount of oxaloacetate is disclosed.

## Claims

### Claim 1

Use of an effective lifespan-extending amount of a composition selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate for the manufacture of a medicament for extending the lifespan of an organism.

### Claim 2 (depends on 1)

The use of claim 1, wherein said composition is formulated for oral administration.

### Claim 3 (depends on 1)

The use of claim 1, wherein said composition is formulated with a buffer.

### Claim 4 (depends on 1)

The use of claim 1, wherein said organism is a mammal.

### Claim 5 (depends on 4)

The use of claim 4, wherein said mammal is a human.

### Claim 6 (depends on 1)

The use of claim 1, wherein said compound is topically administered.

### Claim 7 (depends on 1)

The use of claim 1, wherein said compound is administered parenterally.

### Claim 8

A method of mimicking the beneficial health effect of caloric restriction without reducing caloric intake, comprising:
administering an effective amount of a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, and an oxaloacetate salt.

### Claim 9 (depends on 8)

The method of claim 8, wherein said beneficial health effect is selected from the group consisting of weight loss, improvement of cardiac function, and extension of life span.

### Claim 10 (depends on 8)

The method of claim 8, wherein said compound is formulated for oral administration.

### Claim 11 (depends on 8)

The method of claim 8, wherein said compound further includes a buffer.

### Claim 12 (depends on 8)

The method of claim 8, wherein said organism is a mammal.

### Claim 13 (depends on 12)

The method of claim 12, wherein said mammal is a human.

### Claim 14 (depends on 8)

The method of claim 8, wherein said compound is administered parenterally.

### Claim 15 (depends on 8)

The method of claim 8, further comprising administering a therapeutic agent selected from the group consisting of an antibacterial, an antifungal, a chemotherapeutic agent, an anti-histamine, protein, enzyme, hormone, non-steroidal anti-inflammatory, an immuno-stimulatory compound, and a steroid.

### Claim 16 (depends on 15)

The method of claim 15, wherein said therapeutic agent is administered separately from said compound.

### Claim 17 (depends on 15)

The method of claim 15, wherein said therapeutic agent is administered substantially contemporaneously with said compound.

### Claim 18

A composition for treating symptoms of skin aging, comprising:
an effective amount of a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloaceate salt, alpha-ketoglutarate, and aspartate;
and a pharmaceutically effective carrier formulated for topical delivery.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said pharmaceutically acceptable carrier is selected from the group consisting of a cream, a soap, a shampoo, a conditioner, an ointment, a lotion, a gel, a salve, and an aerosol spray.

### Claim 20 (depends on 18)

The composition of claim 18, further comprising a second beneficial agent selected from the group consisting of an emollient, sunscreen, moisturizer, and buffer.

### Claim 21 (depends on 18)

The composition of claim 18, wherein said symptoms of skin aging are selected from the group consisting of rhytids, wrinkles, jowls, sun damage, dull appearance of skin, loss of skin taughtness, keratosis, hyperpigmentation, melasma, and skin discoloration.

### Claim 22 (depends on 18)

The composition of claim 18, further comprising a lipophilic agent, wherein said lipophilic agent acts to modify the rate of absorption of said composition.

### Claim 23

Use of a composition selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate, and aspartate in the manufacture of a medicament for reducing the signs of skin aging, wherein said composition is formulated for topical administration with a pharmaceutically acceptable carrier.

### Claim 24

A method for protecting DNA and enhancing DNA damage repair from sun exposure, comprising topically administering an effective amount of a composition comprising a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate and a pharmaceutically acceptable carrier.

### Claim 25

An improved animal chow formulation comprising a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate, and aspartate, wherein said chow increases the life span of said animal.

### Claim 26

A method for increasing the activity of the Sir2 gene and/or at least one gene homologue by administering an effective amount of a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate.

### Claim 27 (depends on 26)

The method of claim 26, wherein said compound is administered orally.

### Claim 28 (depends on 26)

The method of claim 26, wherein said compound is formulated with a buffer.

### Claim 29 (depends on 26)

The method of claim 26, wherein said organism is a mammal.

### Claim 30 (depends on 29)

The method of claim 29, wherein said mammal is a human.

### Claim 31 (depends on 26)

The method of claim 26, wherein said compound is topically administered.

### Claim 32 (depends on 26)

The method of claim 26, wherein said compound is administered parenterally.

### Claim 33 (depends on 26)

The method of claim 26, wherein said gene homologue is Sirt1.

### Claim 34

Use of a pharmaceutically effective amount of a composition selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate in the manufacture of a medicament for reducing the incidence of cancer.

### Claim 35 (depends on 34)

The use of claim 34, further comprising administering a chemotherapeutic agent selected from the group consisting of cyclophosphamide, chlorambucil, melphalan, estramustine, iphosphamide, prednimustin, busulphan, tiottepa, carmustin, lomustine, methotrexate, azathioprine, mercaptopurine, thioguanine, cytarabine, fluorouracil, vinblastine, vincristine, vindesine, etoposide, teniposide, dactinomucin, doxorubin, dunorubicine, epirubicine, bleomycin, nitomycin, cisplatin, carboplatin, procarbazine, amacrine, mitoxantron, tamoxifen, nilutamid, and aminoglutemide.

### Claim 36 (depends on 34)

The use of claim 34, wherein said composition is administered orally.

### Claim 37 (depends on 34)

The use of claim 34, wherein said somposition is administered parenterally.

### Claim 38 (depends on 35)

The use of claim 35, wherein said chemotherapeutic agent is administered prior to administering said compound.

### Claim 39 (depends on 35)

The use of claim 35, wherein said chemotherapeutic agent is administered after administering said compound.

### Claim 40 (depends on 35)

The use of claim 35, wherein said chemotherapeutic agent is administered substantially contemporaneously with said compound.

### Claim 41 (depends on 34)

The use of claim 34, wherein said cancer is selected from the group consisting of primary and metastatic malignant solid tumor disease and a hematological malignancy.

### Claim 42 (depends on 41)

The use of claim 41, wherein said hematological malignancy is selected from the group consisting of acute and chronic myelogenous leukemia, acute and chronic lymphatic leukemia, multiple myeloma, Waldenstrom's macroglobulinemia, hairy cell leukemia, myelodisplastic syndrome, polycytaemia vera, and essential thrombocytosis.

### Claim 43

Use of a pharmaceutically effective amount of a composition selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate in the manufacture of a medicament for treating a disease associated with aging, wherein said composition is formulated with a pharmaceutically acceptable carrier.

### Claim 44 (depends on 43)

The use of claim 43, wherein said disease is selected from the group consisting of osteoporosis, bone loss, arthritis, stiffening joints, cataracts, macular degeneration, and heart disease.

### Claim 45 (depends on 43)

The use of claim 43, wherein said disease is a neurodegenerative disease selected from the group consisting of Alzheimer disease and Parkinson's Disease.

### Claim 46

Use of a pharmaceutically effective amount of a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate in the manufacture of a medicament for reducing the symptoms associated with over-consumption of alcohol.

### Claim 47 (depends on 46)

The use of claim 46, wherein said symptoms are selected from the group consisting of headache, poor sense of overall well-being, diarrhea, loss of appetite, shakiness, fatigue, and nausea.

### Claim 48

A composition of matter formulated for topical administration comprising a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate, and aspartate, and at least one of a second therapeutic agent selected from the group consisting of a sunscreen, a cosmetic carrier, a vitamin.

### Claim 51

A therapeutic composition comprising a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate and a therapeutic agent.

### Claim 52

A method of increasing the ratio of NAD+ to NADH in a cell, comprising: administering an effective dose of a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate, and aspartate, wherein said increase in the ratio of NAD+ to NADH in said cell results in mimicking the beneficial health effect of caloric restriction without reducing caloric intake.

### Claim 53

A method of mimicking caloric restriction in a specific tissue of an animal comprising administering a compound selected from the group consisting of oxaloacetate, oxaloacetic acid, an oxaloacetate salt, alpha-ketoglutarate and aspartate, wherein said mimicking is localized to the area of administration of said compound.
